Today: 21 May 2026
CapitaLand Investment (9CI) stock edges up as Feb 11 results date nears; DBS deck highlights fee growth
7 January 2026
1 min read

CapitaLand Investment (9CI) stock edges up as Feb 11 results date nears; DBS deck highlights fee growth

Singapore, Jan 7, 2026, 15:49 SGT — Regular session

Shares of CapitaLand Investment Limited (SGX:9CI) edged up 0.36% to S$2.77 by 3:20 p.m. Singapore time on Wednesday, near the top of the day’s S$2.76-S$2.78 range and not far from a 52-week high of S$2.87.

The Singapore-listed real asset manager is heading into a dense stretch of investor touchpoints, when markets will test whether fee income can keep rising as managers push new funds and recycle capital. Fee-related revenue is the recurring money an asset manager earns for running clients’ assets, while funds under management measures the size of that pool.

Interest-rate expectations add another layer. OCBC head of equity research Carmen Lee described the 2026 backdrop as “constructive”, while Macquarie analysts forecast the Singapore Overnight Rate Average (SORA) — a key benchmark rate — could drop below 1% by mid-year and urged investors to rotate into rate-sensitive Singapore REITs, The Business Times reported. The Business Times

A filing showed CapitaLand Investment will publish its unaudited full-year 2025 results on Feb. 11 before the market opens, after a run of reporting dates for listed trusts it manages, including CapitaLand Malaysia Trust on Jan. 28 and CapitaLand Ascott Trust on Jan. 29.

The company will hold a results briefing for analysts and the media at 9:00 a.m. on results day and will stream a live webcast, it said.

In slides released for DBS Global Financial Markets’ Regional Property Conference on Jan. 7, CapitaLand Investment flagged S$1.568 billion in revenue for the first nine months of 2025 and said fee-related revenue rose to S$882 million, helped by higher event-driven fees and contributions from new funds. The deck also cited S$3.7 billion of equity raised across its listed and private funds in 2025 and S$2.3 billion of asset monetisation year-to-date, with funds under management at S$120 billion.

But investors remain wary that deal activity can slow quickly if credit conditions tighten or if property valuations — especially in China — stay under pressure, crimping transaction-related fees. A weaker fundraising tape would also weigh on fee growth, the main engine of earnings for asset-light managers.

Stock Market Today

  • Nakamoto to Execute 1-for-40 Reverse Stock Split After Bitcoin Price Collapse
    May 20, 2026, 10:41 PM EDT. Bitcoin treasury firm Nakamoto (NAKA) will implement a 1-for-40 reverse stock split to meet Nasdaq's $1 minimum bid price requirement, following a more than 99.5% plunge from its 52-week high. After Q1 losses of $239 million tied to Bitcoin's price decline, NAKA shares dropped to a historic low near $0.15. The split will reduce outstanding shares from 696.1 million to 17.4 million, effective May 22. Nakamoto holds over 5,000 Bitcoin valued above $388 million but has sold $42 million worth in recent quarters. Bitcoin itself trades around $77,927, up 1.6% in 24 hours, yet remains over 38% below its October peak.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Previous Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop